Xianwen Shang

Tianjin Medical University Cancer Institute and Hospital

Papers

1

Total Citations

13

H-Index

1

About

No biography available yet.

Research Focus

Adverse effect1 · 13 citations
Cancer1 · 13 citations
Chemotherapy1 · 13 citations
Clinical trial1 · 13 citations
Immunotherapy1 · 13 citations
Interim analysis1 · 13 citations
Internal medicine1 · 13 citations
Medicine1 · 13 citations
Neoadjuvant therapy1 · 13 citations
Oncology1 · 13 citations
Paclitaxel1 · 13 citations
Pembrolizumab1 · 13 citations

Key Achievements

1
H-Index
1
Papers
13
Total Citations
13
Avg Citations/Paper
🏆 Most Cited Paper
LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial
13 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Tianjin Medical University Cancer Institute and Hospital

Top Papers

  1. 1
    LBA3 Safety and efficacy of pembrolizumab combined with paclitaxel and cisplatin as a neoadjuvant treatment for locally advanced resectable (stage III) esophageal squamous cell carcinoma (Keystone-001): Interim analysis of a prospective, single-arm, single-center, phase II trial
    13 citations · 2021

Key Collaborators

ZMZhao Ma1 shared papersJYJ. Yue1 shared papersCCC. Chen1 shared papersWZW. Zhang1 shared papersLLL. Liu1 shared papersHJHongjing Jiang1 shared papersGZGang Zhao1 shared papersXRXiubao Ren1 shared papersCZChao Zhang1 shared papersXDXingyu Duan1 shared papersBMBin Meng1 shared papers
Not generated yet